Biologics and Biosimilars Market Size, Share and Trends 2026 to 2035

Revenue, 2025

USD 610.41 Bn

Forecast Year, 2035

USD 2,426.85 Bn

CAGR, 2026 - 2035

14.80%

Report Coverage

Global

What is Biologics and Biosimilars Market Size in 2026?

The global biologics and biosimilars market size was calculated at USD 610.41 billion in 2025 and is predicted to increase from USD 700.76 billion in 2026 to approximately USD 2,426.85 billion by 2035, expanding at a CAGR of 14.80% from 2026 to 2035. The market is driven by growing emphasis of market players on developing advanced technologies for manufacturing biologics and biosimilars, which undergo rigorous evaluation by regulatory agencies such as the FDA and EMA and are widely used to treat cancers, autoimmune disorders, and chronic diseases like diabetes.

Key Takeaways

• North America dominated the market with the largest share of 46.70% in 2025.
• Asia Pacific is expected to grow at the fastest CAGR in the market during the forecast period.
• By product, the monoclonal antibodies segment captured around 52.70% share in 2025.
• By product, the vaccines segment is projected to grow at a significant CAGR of 8.40% during the forecast period.
• By molecule classification, the originator biologics segment contributed the largest market share of 85.70% in 2025.
• By molecule classification, the biosimilars segment is expected to grow at a CAGR of 11.60% during the forecast period.
• By therapy area, the oncology segment held a major market share of 28.60% in 2025.
• By therapy area, the metabolic and endocrine disorders segment is expected to grow at a CAGR of 9.40% during the forecast period.
• By route of administration, the intravenous segment contributed the largest market share of 41.70% in 2025.
• By route of administration, the subcutaneous segment is expected to grow at a CAGR of 9.40% during the forecast period.
• By production expression system, the mammalian cell expression segment held the biggest market share of 63.80% in 2025.
• By production expression system, the plant and transgenic expression segment is poised to grow at a remarkable CAGR of 10.20% during the forecast period.

Market Overview

The biologics and biosimilars market cover therapeutic products manufactured using living systems and their biosimilar equivalents developed to match approved reference biologics. It includes monoclonal antibodies, vaccines , recombinant hormones, cytokines, and blood factors across major disease areas. Market value includes originator biologics and biosimilars sold through hospitals, specialty channels, and retail pharmacy networks, supported by cold-chain distribution and pharmacovigilance. Growth is driven by specialty care demand, new biologic launches, expanded indications, and increasing biosimilar adoption after patent expiry.

How are Technological Advancements Influencing the Biologics and Biosimilars Market?

Technological advancements, particularly the integration of artificial intelligence (AI), are significantly transforming the biologics and biosimilars market. AI is improving drug discovery, development, and manufacturing by enabling faster identification of therapeutic candidates and enhancing the precision of complex biologic formulations. Technologies such as digital twins and advanced manufacturing optimization help stimulate production processes, improve efficiency, reduce costs, and support environmentally sustainable manufacturing while maintaining strict regulatory standards.

In addition, AI plays an important role in clinical trials and patient-focused treatment approaches. Machine learning algorithms analyze large biological and clinical datasets to predict patient responses, optimize dosing, and improve safety outcomes. These capabilities help streamline development timelines and support faster regulatory approvals, ultimately increasing access to effective and affordable biologic therapies worldwide.

Biologics and Biosimilars Market Trends

• Growing number of biosimilar approvals globally: Many countries are witnessing a steady rise in the approval of biosimilar medicines as healthcare systems search for more affordable alternatives to high-cost biologic drugs. Biosimilars are developed to closely match already approved biologic therapies in terms of safety, effectiveness, and quality. Their availability helps reduce treatment expenses and improves patient access to important therapies used for conditions such as cancer, autoimmune disorders, and other chronic diseases.
• Advancements in bioprocessing and manufacturing technologies:Continuous improvements in bioprocessing technologies are making the production of biologics more efficient and scalable. Innovations such as recombinant DNA techniques, automated systems, and robotic manufacturing processes allow companies to streamline production while maintaining strict quality standards. These technologies also help reduce operational costs and improve productivity, enabling manufacturers to meet the growing demand for biologic medicines.
• Patent expirations of major biologic drugs: The expiration of patents for several widely used biologic therapies is opening new opportunities for biosimilar manufacturers. Once the exclusivity period of branded biologics ends, other companies can introduce biosimilar versions at lower prices. This increases market competition and helps expand access to life-saving treatments.
• Increasing research and development activities: Pharmaceutical and biotechnology companies are investing heavily in research and development to discover new biologic therapies and develop biosimilars of existing products. These efforts focus on targeting specific molecular pathways, which can lead to more effective and precise treatment options for various diseases.
• Rising demand for personalized medicine: The healthcare industry is increasingly moving toward personalized or precision medicine, where treatments are designed based on an individual's genetic profile or specific disease characteristics. Biologics play a key role in this approach because they can be engineered to target specific biomarkers or molecular pathways, enabling more tailored and effective treatments for patients.

Market Scope

Segment Insights

Product CategoryInsights

Why Did the Monoclonal Antibodies Segment Dominate the Market?

The monoclonal antibodies segment dominated the biologics and biosimilars market with the highest share of 52.70% in 2025, driven by their high therapeutic effectiveness and ability to precisely target disease-specific antigens. These products are widely used for treating complex diseases such as cancer, autoimmune disorders, and inflammatory conditions because they specifically target abnormal cells while minimizing damage to healthy tissues. Strong clinical pipelines and increasing approvals from regulatory authorities such as the U.S. Food and Drug Administration and the European Medicines Agency have further contributed to their dominant position. Additionally, the expiration of patents for several blockbuster biologics has enabled biosimilar monoclonal antibodies to enter the market, improving treatment access and affordability while encouraging pharmaceutical companies to expand their monoclonal antibody portfolios.

The vaccines segment is expected to grow at a CAGR of 8.40% throughout the forecast period due to increasing global demand for immunization against infectious diseases and rising awareness of preventive healthcare. Technological advancements in vaccine development, such as mRNA and recombinant platforms, have enhanced efficacy, safety, and production scalability. Additionally, government immunization programs, increased funding for public health initiatives, and the ongoing need for pandemic preparedness are driving widespread adoption of vaccines, fueling growth in this segment.

The other biologics segment is expected to grow at a significant rate during the projection period, supported by growing demand for specialized therapies for rare and chronic conditions. This category includes biologic products such as interferons, enzyme replacement therapies, and low-molecular-weight heparins that are often used to treat specific medical conditions. Although these therapies typically address smaller patient populations, increasing awareness and improved diagnostics are driving their demand. Advances in biologic manufacturing technologies and supportive regulatory frameworks are also encouraging pharmaceutical companies to invest in these areas. Additionally, growing investments in contract development and manufacturing organizations (CDMOs) and favorable reimbursement policies are expected to support the steady expansion of this segment.

Molecule Classification Insights

What Made Originator Biologics the Dominant Segment in the Biologics and Biosimilars Market?

The originator biologics segment dominated the market with the highest share of 85.70% in 2025, primarily due to their strong clinical track record, established safety profiles, and wide adoption in the treatment of complex diseases. These biologics have long been the standard treatment for conditions such as cancer, autoimmune diseases, and metabolic disorders. Their dominance is also supported by extensive clinical evidence, strong research pipelines, and continued investments from leading pharmaceutical companies. Physicians often rely on originator biologics because they are backed by years of safety and efficacy data. As a result, despite the growing development of biosimilars, originator biologics continue to maintain its leading position in the market.

The biosimilars segment is expected to grow at a robust CAGR of 11.6% during the forecast period, mainly driven by the rising need for cost-effective treatment options. Biosimilars offer similar safety and efficacy as reference biologics but at a comparatively lower cost, helping reduce the overall burden of expensive biologic therapies. The increasing prevalence of chronic diseases and growing healthcare expenditures are further accelerating their adoption. In addition, supportive regulatory pathways, improving physician confidence, and expanding biosimilar product launches are encouraging their use across healthcare systems, making biosimilars an important growth area within the market.

Therapy Area Insights

Why Did the Oncology Segment Dominate the Market in 2025?

The oncology segment dominated the biologics and biosimilars market with a major share of 28.6% in 2025, largely due to the growing global burden of cancer and the increasing demand for targeted treatment options. Biologic therapies, particularly monoclonal antibodies and supportive care products such as growth factors, have significantly improved cancer treatment by targeting specific tumor cells while minimizing damage to healthy tissues. The introduction of oncology biosimilars has also helped reduce the high cost of cancer therapies, enabling healthcare systems to treat a larger number of patients. Rising cancer incidence worldwide, along with continuous research and supportive regulatory policies, is further strengthening the adoption of biologic and biosimilar therapies in oncology across hospitals and specialized treatment centers.

The metabolic and endocrine disorders segment is expected to expand at the fastest CAGR of 9.40% during the forecast period, driven by the increasing prevalence of conditions such as diabetes, hormonal disorders, and other metabolic diseases. The growing burden of these conditions is increasing the need for more effective treatment options. Biologic therapies are gaining attention because they offer targeted approaches that address specific disease mechanisms. Improved diagnostic capabilities and greater awareness of metabolic diseases are also encouraging earlier and more effective treatment. Additionally, ongoing research and investments in developing advanced biologic therapies are expected to further support the expansion of this segment in the coming years.

Route of Administration Insights

What Made Intravenous the Dominant Segment in the Market?

The intravenous segment dominated the biologics and biosimilars market with the highest share of 41.7% in 2025, mainly because many biologic therapies require controlled delivery directly into the bloodstream for faster and more effective therapeutic action. This route is widely used in hospitals and clinical settings, particularly for treatments in oncology, autoimmune diseases, and other complex conditions. Intravenous administration also allows healthcare professionals to carefully monitor dosing and patient response, ensuring safety and treatment effectiveness. The availability of well-established infusion infrastructure in hospitals and the widespread use of biologic infusion therapies continue to support the strong position of this segment in the market.

The subcutaneous segment is expected to grow at the fastest CAGR of 9.40% during the forecast period, driven by increasing demand for convenient and patient-friendly treatment options. This route allows biologic drugs to be injected under the skin, making it suitable for self-administration at home and reducing the need for hospital visits. As healthcare systems increasingly focus on improving patient convenience and long-term disease management, pharmaceutical companies are developing more biologic formulations suitable for subcutaneous delivery. These advantages are expected to significantly drive the adoption of subcutaneous biologic therapies in the coming years.

Production Expression System Insights

Why Does the Mammalian Cell Expression Segment Dominate the Market in 2025?

The mammalian cell expression segment dominated the biologics and biosimilars market with the highest share of 63.8% in 2025, as it remains the most widely used system for producing complex biologic drugs. This system allows proteins to be produced in an environment that closely resembles human biological processes, ensuring correct protein folding and biological activity. Many important biologic therapies, including recombinant insulin and interferons, are manufactured using mammalian cell expression systems. Advances in cell-line engineering, cell culture methods, and bioprocess technologies have improved production efficiency and scalability. As a result, a significant portion of biologic drug candidates currently in development relies on mammalian expression platforms for large-scale manufacturing.

The plant and transgenic expression segment is expected to grow at a CAGR of 10.2% during the forecast period. These systems are gaining attention due to their potential for cost-effective and scalable production of biologic products. Plant-based platforms can produce complex proteins with lower manufacturing costs and reduced risk of contamination from human pathogens. Increasing research activities and advancements in genetic engineering technologies are encouraging pharmaceutical and biotechnology companies to explore plant and transgenic systems for the development of next-generation biologics and vaccines.

Regional Insights

North America Biologics and Biosimilars Size and Growth 2026 to 2035

The North America biologics and biosimilars market size is estimated at USD 285.06 billion in 2025 and is projected to reach approximately USD 1,145.47 billion by 2035, with a 14.92% CAGR from 2026 to 2035.

What Made North America the Dominant Region in the Biologics and Biosimilars Market?

North America dominated the biologics and biosimilars market with the highest share of 46.7% in 2025, driven by strong healthcare infrastructure, significant investments in research and development, and a favorable regulatory environment. The region benefits from well-established regulatory frameworks developed by the U.S. Food and Drug Administration, which have streamlined biosimilar approval pathways and introduced interchangeability guidelines, improving market accessibility for these therapies. In addition, the growing demand for cost-effective treatment options, increasing pressure from healthcare payers to control drug costs, and the rising prevalence of chronic diseases are contributing to market expansion.

North America also hosts many leading pharmaceutical and biotechnology companies that actively invest in the development of biologics and biosimilars. Biologic therapies are widely used across therapeutic areas such as oncology , immunology, and endocrinology, and biosimilars are increasingly being integrated into treatment protocols, further supporting the region's market growth.

U.S. Biologics and Biosimilars Size and Growth 2026 to 2035

The U.S. biologics and biosimilars market size is calculated at USD 213.80 billion in 2025 and is expected to reach nearly USD 864.83 billion in 2035, accelerating at a strong CAGR of 15.00% between 2026 to 2035.

U.S. Market Analysis

U.S. is expected to maintain a leading position in the North American biologics and biosimilars market, supported by its large patient population and strong demand for advanced biologic therapies. The country remains one of the largest consumers of biologic medicines globally, while the adoption of biosimilars has been steadily increasing as healthcare providers and payers seek more cost-effective treatment options. Greater inclusion of biosimilars in insurance formularies and growing confidence among healthcare professionals are further encouraging their use.

The market in the U.S. is also supported by a highly developed healthcare ecosystem that promotes innovation and research. The presence of leading pharmaceutical companies, medical research institutions, and advanced healthcare facilities contributes to the continuous development of biologic therapies. In addition, a well-established regulatory system overseen by the U.S. Food and Drug Administration ensures strict standards for safety and quality, while providing clear pathways for the approval of biologics and biosimilars.

What Makes Asia Pacific the Fastest-Growing Region in the Biologics and Biosimilars Market?

Asia Pacific is expected to grow at the fastest rate in the market, driven by the rising prevalence of chronic diseases, expanding middle-class populations, and increasing healthcare spending. Countries such as Japan, South Korea, and Australia are playing a key role as both producers and consumers of biosimilars, supported by government policies that encourage local manufacturing and improve treatment affordability. Regulatory frameworks across the region are gradually aligning with global standards, helping accelerate the development and approval of biosimilar therapies.

In addition, growing public healthcare initiatives and rising investments in biotechnology research are strengthening the regional market. The region is also witnessing an increase in clinical trial activities and international collaborations aimed at expanding biosimilar development and commercialization, positioning the region as an important contributor to the global biologics and biosimilars landscape.

India Market Analysis

India is emerging as a key player in the biologics and biosimilars market due to its strong pharmaceutical manufacturing base and expanding biotechnology sector. Domestic companies are actively developing biosimilars for both local and global markets. The rising prevalence of chronic diseases and the need for affordable biologic therapies are driving demand across the country. In addition, supportive regulations from the Central Drugs Standard Control Organization and increasing investments in research and development are further strengthening India's position in the global biosimilars landscape.

How is the Opportunistic Rise of Europe in the Biologics and Biosimilars Market?

urope is expected to experience significant growth in the market, supported by early regulatory initiatives and strong acceptance among healthcare professionals. The region has played a pioneering role in biosimilar adoption, largely due to the structured approval pathways introduced by the European Medicines Agency, which enabled quicker access to these therapies. Countries such as Germany, the Uk, and France have implemented clear pricing strategies, reimbursement policies, and substitution frameworks that encourage the use of biosimilars.

In addition, hospital tender programs and incentives for switching from reference biologics to biosimilars have significantly increased their uptake, particularly in areas such as oncology and rheumatology. As a result, biosimilars are now widely integrated into routine clinical practice across the region, making Europe a global benchmark for biosimilar adoption and market development.

Germany Market Analysis

The market in Germany is driven by its well-structured healthcare system and policies that encourage biosimilar adoption. Physicians have considerable autonomy in prescribing treatments, while financial incentives and prescription quota systems promote the use of biosimilars across multiple therapeutic areas. Strong competition among pharmaceutical manufacturers and active involvement of regional healthcare authorities further support market growth. In addition, high physician awareness and extensive post-marketing surveillance data have increased confidence in switching from reference biologics to biosimilars, particularly for monoclonal antibodies and insulin therapies. As a result, Germany is often regarded as a leading example of successful biosimilar integration in healthcare.

UK Market Analysis

The UK has adopted a strong cost-focused strategy to promote the use of biosimilars within its healthcare system. The National Health Service (NHS) encourages early adoption of biosimilars through competitive tendering processes and their inclusion in treatment formularies. In addition, switching programs supported by NHS England and regional healthcare trusts have helped accelerate the transition from reference biologics to biosimilar alternatives. The UK government views biosimilars as an important strategy for controlling healthcare spending, as the cost savings generated can be reinvested to improve healthcare services and expand treatment access for patients.

Biologics and Biosimilars Market Value Chain Analysis

• Research and Development:
  This stage focuses on developing innovative drugs, biosimilars, and minimally invasive treatments to improve safety, efficacy, and patient outcomes.
  Key Players: Roche, Johnson and Johnson, AbbVie, Merck and Co., Pfizer, Novartis, Sanofi
• Clinical Research:
  This stage involves conducting trials to validate safety, effectiveness, and long-term benefits while supporting approvals and reimbursement.
  Key Players: Pfizer, Novartis, Sanofi, AstraZeneca, Bristol Myers Squibb, Sanofi
• Regulatory Affairs:
  This stage ensures therapies meet safety standards and obtain approvals before commercialization and market entry.
  Key Players: Johnson and Johnson, Merck and Co., Pfizer, Novartis, AstraZeneca, Eli Lilly

Biologics and Biosimilars Market Companies

• Roche
• Johnson and Johnson
• AbbVie
• Merck and Co.
• Pfizer
• Novartis
• Amgen
• Sanofi
• AstraZeneca
• Bristol Myers Squibb
• GSK
• Eli Lilly
• Sandoz
• Samsung Bioepis
• Celltrion

Segments Covered in the Report

By Product Category

• Monoclonal antibodies
• Vaccines
• Recombinant hormones
• Cytokines and interferons
• Blood factors
• Other biologics

By Molecule Classification

• Originator biologics
• Biosimilars

By Therapy Area

• Oncology
• Autoimmune and inflammatory diseases
• Metabolic and endocrine disorders
• Infectious diseases
• Rare diseases
• Other therapy areas

By Route of Administration

• Intravenous
• Subcutaneous
• Intramuscular
• Other routes

By Production Expression System

• Mammalian cell expression
• Microbial expression
• Plant and transgenic expression
• Other expression systems

By Region

• North America
• Latin America
• Europe
• Asia-pacific
• Middle and East Africa